S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%
Next Bullish Trade
Sign in
NNVC

NanoViricides, Inc. ASE · NNVC

$1.75 -0.02 (-1.13%)
Extended · +1.37σ Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · NNVC

Momentum reads · latest daily bar
Last
$1.75
-0.02 (-1.13%)
Mkt cap
$40M
Healthcare
RSI(14)
62.6
neutral
Stochastic %K
82.8
overbought
MFI(14)
83.0
overbought
ADX(14)
21.7
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 — $-0.0B $-0.0B $-0.0B — —
2025-12-31 — $-0.0B $-0.0B $-0.0B — —
2025-09-30 — $-0.0B $-0.0B $-0.0B — —
2025-06-30 — $-0.0B $-0.0B $-0.0B — —
2025-03-31 — $-0.0B $-0.0B $-0.0B — —
2024-12-31 $nanB $nanB $nanB — nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare NNVC vs peers

Line NNVC up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing NNVC no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with NNVC

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
NNVC ★ $0B — -5.0 — -4.6 4.1 — — — -10.92%
LLY $1,051B 41.8 26.3 14.6 29.8 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.4 19.7 6.2 18.2 7.5 68.1% 6.6% -1.0% —
MRK $315B 35.9 13.2 4.8 12.2 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.1 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.7 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.3 19.5 4.4 21.4 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 7.19%

HolderShares% out
Vanguard Capital Management LLC 511,477 2.23%
Geode Capital Management, LLC 225,381 0.98%
UBS Group AG 213,359 0.93%
Blackrock Inc. 158,752 0.69%
Renaissance Technologies, LLC 134,900 0.59%
Miller Financial Services LLC 105,000 0.46%
Susquehanna International Group, LLP 99,031 0.43%
Vanguard Fiduciary Trust Co 90,060 0.39%
Squarepoint Ops LLC 58,138 0.25%
State Street Corporation 54,206 0.24%

Insider activity · 90d

No insider trades for NNVC in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$6.0
Mean
$6.0
High
$6.0
Analysts
2
Recommendation distribution · period 2026-07-01
2
4
1
Revision trend (2026-04-01 → 2026-07-01): net 6 → 6 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-17 FORM 8-K view ·
8-K 2026-05-21 FORM 8-K view ·
8-K 2026-05-20 FORM 8-K view ·
10-Q 2026-05-15 10-Q view ·
10-Q 2026-02-17 10-Q view ·
8-K 2025-11-26 FORM 8-K view ·
8-K 2025-11-14 FORM 8-K view ·
10-Q 2025-11-14 10-Q view ·
DEF 14A 2025-10-08 DEF 14A view ·
8-K 2025-10-01 FORM 8-K view ·
10-K 2025-09-29 10-K view ·
10-Q 2025-05-15 10-Q view ·
10-Q 2025-02-14 10-Q view ·
4 2025-01-28 PRIMARY DOCUMENT view ·
8-K 2024-12-12 FORM 8-K view ·
10-Q 2024-11-14 10-Q view ·
DEF 14A 2024-10-15 DEF 14A view ·
10-K 2024-09-27 10-K view ·
8-K 2024-08-09 FORM 8-K view ·
10-Q 2024-05-15 10-Q view ·
8-K 2024-04-05 FORM 8-K view ·
8-K 2024-02-16 FORM 8-K view ·
10-Q 2024-02-14 10-Q view ·
8-K 2024-01-19 FORM 8-K view ·
DEF 14A 2023-12-04 DEF 14A view ·
10-Q 2023-11-14 10-Q view ·
8-K 2023-11-07 FORM 8-K view ·
10-K 2023-10-13 10-K view ·
8-K 2023-09-01 FORM 8-K view ·
8-K 2023-05-25 FORM 8-K view ·
10-Q 2023-05-15 10-Q view ·
8-K 2023-03-31 FORM 8-K view ·
10-Q 2023-02-14 10-Q view ·
8-K 2023-02-13 FORM 8-K view ·
8-K 2022-12-22 FORM 8-K view ·
DEF 14A 2022-11-15 DEF 14A view ·
10-Q 2022-11-14 10-Q view ·
10-K 2022-10-13 10-K view ·
8-K 2022-10-11 FORM 8-K view ·
4 2022-08-10 FORM 4 view ·
10-Q 2022-05-16 10-Q view ·
10-Q 2022-02-14 10-Q view ·
8-K 2021-11-26 FORM 8-K view ·
10-Q 2021-11-15 FORM 10-Q view ·
10-K 2021-10-12 FORM 10-K view ·
DEF 14A 2021-10-12 DEF 14A view ·
8-K 2021-09-21 FORM 8-K view ·
8-K 2021-09-15 FORM 8-K view ·
10-Q 2021-05-14 FORM 10-Q view ·
10-Q 2021-02-16 FORM 10-Q view ·
8-K 2020-12-10 FORM 8-K view ·
8-K 2020-11-19 FORM 8-K view ·
10-Q 2020-11-16 FORM 10-Q view ·
DEF 14A 2020-10-26 DEF 14A view ·
10-K 2020-10-13 FORM 10-K view ·
8-K 2020-09-04 FORM 8-K view ·
8-K 2020-08-03 FORM 8-K view ·
8-K 2020-07-13 FORM 8-K view ·
10-Q 2020-06-22 FORM 10-Q view ·
8-K 2020-06-04 FORM 8-K view ·

About NNVC

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. …

Options picks · NNVC

ITM + OTM ideas from the latest scan

Loading…

Congress trades · NNVC

STOCK Act disclosures

Loading…

SEC filings & insiders · NNVC

EDGAR · live

Loading…

Holders · NNVC

Institutions & insider activity

Loading…